India, Oct. 19 -- GSK plc (GSK) announced that the U.S. FDA has approved Jemperli as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) locally advanced rectal cancer. The approval was granted under the FDA's accelerated approval pathway and is based on results from the Phase II AZUR-1 trial.
Offering an Alternative to Chemotherapy, Radiation and Surgery
Treatment for locally advanced rectal cancer has traditionally involved a combination of chemotherapy, radiation therapy and surgery. While these treatments can be effective, they may also lead to long-term complications affecting bowel, urinary and sexual function.
According to GSK, Jemperli monot...